HealthEquity price target raised to $85 from $75 at Raymond James

Raymond James analyst C. Gregory Peters raised the firm’s price target on HealthEquity to $85 from $75 and keeps an Outperform rating on the shares. The stock was down ~5% last week after reporting Q3 results and raising FY23 guidance due in part to the broader market performance and management’s conservative FY24 cash yield guidance relative to the street’s increasingly optimistic expectations, Peters tells investors in a research note.